Use of circulating tumoral DNA to guide treatment for metastatic melanoma
The management of metastatic cutaneous melanoma is conditioned by the identification of BRAF-activating mutations in tumor DNA. Tumor genotyping is usually performed on DNA extracted from tissue samples. However, these invasive samples are rarely repeated during follow-up, and their analysis requires a sample pre-treatment which may take several weeks. Circulating tumor DNA (ctDNA), released into blood by cancer cells, is a good alternative to tissue sampling. ctDNA is not subject to tumor heterogeneity, and can be analyzed rapidly, making possible the detection of mutations in emergency or in patients whose tumor cannot be sampled. ctDNA can also be analyzed repeatedly during follow-up, for postresection minimal residual disease assessment, for therapeutic response monitoring and for early relapse detection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Pharmacogenomics - 20(2019), 18 vom: 01. Dez., Seite 1259-1270 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Herbreteau, Guillaume [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BRAF |
|---|
| Anmerkungen: |
Date Completed 22.07.2020 Date Revised 22.07.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/pgs-2019-0097 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM302031545 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM302031545 | ||
| 003 | DE-627 | ||
| 005 | 20231225105845.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/pgs-2019-0097 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1006.xml |
| 035 | |a (DE-627)NLM302031545 | ||
| 035 | |a (NLM)31596166 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Herbreteau, Guillaume |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Use of circulating tumoral DNA to guide treatment for metastatic melanoma |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.07.2020 | ||
| 500 | |a Date Revised 22.07.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The management of metastatic cutaneous melanoma is conditioned by the identification of BRAF-activating mutations in tumor DNA. Tumor genotyping is usually performed on DNA extracted from tissue samples. However, these invasive samples are rarely repeated during follow-up, and their analysis requires a sample pre-treatment which may take several weeks. Circulating tumor DNA (ctDNA), released into blood by cancer cells, is a good alternative to tissue sampling. ctDNA is not subject to tumor heterogeneity, and can be analyzed rapidly, making possible the detection of mutations in emergency or in patients whose tumor cannot be sampled. ctDNA can also be analyzed repeatedly during follow-up, for postresection minimal residual disease assessment, for therapeutic response monitoring and for early relapse detection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a BRAF | |
| 650 | 4 | |a circulating DNA | |
| 650 | 4 | |a ctDNA | |
| 650 | 4 | |a melanoma | |
| 650 | 4 | |a mutation | |
| 650 | 4 | |a tumor | |
| 650 | 7 | |a Biomarkers, Pharmacological |2 NLM | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a Circulating Tumor DNA |2 NLM | |
| 650 | 7 | |a BRAF protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins B-raf |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 700 | 1 | |a Charpentier, Sandrine |e verfasserin |4 aut | |
| 700 | 1 | |a Vallée, Audrey |e verfasserin |4 aut | |
| 700 | 1 | |a Denis, Marc G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacogenomics |d 2000 |g 20(2019), 18 vom: 01. Dez., Seite 1259-1270 |w (DE-627)NLM111671396 |x 1744-8042 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2019 |g number:18 |g day:01 |g month:12 |g pages:1259-1270 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/pgs-2019-0097 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2019 |e 18 |b 01 |c 12 |h 1259-1270 | ||